T
Tom Vink
Researcher at Genmab
Publications - 69
Citations - 5021
Tom Vink is an academic researcher from Genmab. The author has contributed to research in topics: Monoclonal antibody & Von Willebrand factor. The author has an hindex of 25, co-authored 69 publications receiving 4638 citations. Previous affiliations of Tom Vink include Utrecht University.
Papers
More filters
Journal ArticleDOI
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
Marijn Van Der Neut Kolfschoten,Janine Schuurman,Mario Losen,Wim K. Bleeker,Pilar Martinez-Martinez,Ellen Vermeulen,Tamara H. den Bleker,Luus Wiegman,Tom Vink,Lucien A. Aarden,Marc H. De Baets,Marc H. De Baets,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Rob C. Aalberse,Paul W. H. I. Parren +15 more
TL;DR: IgG4 Fab arm exchange is suggested to be an important biological mechanism that provides the basis for the anti-inflammatory activity attributed to IgG4 antibodies.
Journal ArticleDOI
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
Michel de Weers,Yu-Tzu Tai,Michael S. van der Veer,Joost M. Bakker,Tom Vink,Daniëlle C H Jacobs,Lukas A. Oomen,Matthias Peipp,Thomas Valerius,Jerry W. Slootstra,Tuna Mutis,Wim K. Bleeker,Kenneth C. Anderson,Henk M. Lokhorst,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Paul W. H. I. Parren +16 more
TL;DR: The results show the versatility of daratumumab to effectively kill CD38-expressing tumor cells, including patient MM cells, via diverse cytotoxic mechanisms, and support clinical development of darsatumab for the treatment of CD 38-positive MM tumors.
Journal ArticleDOI
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Jessica L. Teeling,Wendy J.M. Mackus,Luus Wiegman,Jeroen van den Brakel,Stephen A. Beers,Ruth R. French,Tom van Meerten,Saskia B. Ebeling,Tom Vink,Jerry W. Slootstra,Paul W. H. I. Parren,Martin J. Glennie,Jan G.J. van den Winkel,Jan G.J. van den Winkel +13 more
TL;DR: It is concluded that recognition of the novel epitope cooperates with slow off-rate in determining the activity of CD20 Ab in activation of complement and induction of tumor cell lysis.
Patent
Heterodimeric antibody fc-containing proteins and methods for production thereof
Aran F. Labrijn,Joyce I. Meesters,Ewald T. J. van den Bremer,Joost J. Neijssen,Patrick Van Berkel,Bart De Goeij,Tom Vink,Jan G. J. van de Winkel,Janine Schuurman,Paul W. H. I. Parren +9 more
TL;DR: Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins are discussed in this paper, where the authors present a method for producing bispeccific antibodies.
Journal ArticleDOI
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
Matthias Peipp,Jeroen J. Lammerts van Bueren,Tanja Schneider-Merck,Wim K. Bleeker,Michael Dechant,Thomas Beyer,Roland Repp,Patrick Van Berkel,Tom Vink,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Paul W. H. I. Parren,Thomas Valerius +12 more
TL;DR: It is demonstrated for the first time that lack of fucose does not generally increase the ADCC activity of therapeutic antibodies and that the impact of Fc glycosylation on ADCC is critically dependent on the recruited effector cell type.